Cardiovascular Medicine

2 pages, 162 KB

Open AccessEditorial

Bekanntmachungen/Informations

by Cardiovascular Medicine

Cardiovasc. Med. 2008, 11(9), 295; https://doi.org/10.4414/cvm.2008.01353 - 26 Sep 2008

Viewed by 59

Abstract

Regelmässige Veranstaltungen kardiologischer Abteilungen/Colloques des Services de cardiologie [...] Full article

2 pages, 203 KB

Open AccessCommunication

Preisverleihungen, SGK-Jahreskongress 2008, Bern

by Gaetano Thiene, Michele Miragoli, Peter Wenaweser, Matthias Wachter and Irina Agarkova

Cardiovasc. Med. 2008, 11(9), 293; https://doi.org/10.4414/cvm.2008.01351 - 26 Sep 2008

Viewed by 64

Abstract

Im Rahmen des Jahreskongresses der Schweizerischen Gesellschaft für Kardiologie vom 28–30 Mai 2008 in Bern wurden folgende Preise verliehen [...] Full article

3 pages, 206 KB

Open AccessCommunication

Population-Based Hypertension Screening in Preschool Children

by Giacomo D. Simonetti, Elke Wühl and Franz Schaefer

Cardiovasc. Med. 2008, 11(9), 290; https://doi.org/10.4414/cvm.2008.01346 (registering DOI) - 26 Sep 2008

Cited by 1 | Viewed by 57

Abstract

Background Hypertension is the leading risk factor for cardiovascular diseases in adults [...] Full article

2 pages, 420 KB

Open AccessInteresting Images

Benign Left Atrial Glomangiopericytoma

by Michel Grobéty, Gregory Katchatourov, François Perret, Stephan Schäfer and Jean-Jacques Goy

Cardiovasc. Med. 2008, 11(9), 288; https://doi.org/10.4414/cvm.2008.01347 (registering DOI) - 26 Sep 2008

Cited by 1 | Viewed by 60

Abstract

Case report This 47-year-old woman had a history of Hodgkin disease treated with chemotherapy and irradiation at the age of seventeen [...] Full article

► Show Figures

Figure 1

2 pages, 429 KB

Open AccessInteresting Images

The Genetic Connection

by Venkata M. Alla, Showri M. Karnam and William P. Biddle

Cardiovasc. Med. 2008, 11(9), 286; https://doi.org/10.4414/cvm.2008.01348 - 26 Sep 2008

Viewed by 70

Abstract

Case report A young Caucasian male with long standing severe debilitating muscle weakness and chronic respiratory failure (ventilator dependant) was transferred to the Intensive care unit for management of ventilator associated pneumonia [...] Full article

► Show Figures

Figure 1

8 pages, 271 KB

Open AccessEditorial

Fondaparinux: A New Antithrombotic Treatment Strategy in Venous Thromboembolism and Acute Coronary Syndromes

by Jean-Pierre Bassand

Cardiovasc. Med. 2008, 11(9), 278; https://doi.org/10.4414/cvm.2008.01350 - 26 Sep 2008

Viewed by 117

Abstract

Fondaparinux (Arixtra^®) is a synthetic selective factor Xa inhibitor. On the grounds of its favorable benefit-risk ratio, fondaparinux is approved for the prevention and treatment of venous thromboembolism. Two large trials in about 32000 patients recently evaluated fondaparinux in the treatment [...] Read more.

Fondaparinux (Arixtra^®) is a synthetic selective factor Xa inhibitor. On the grounds of its favorable benefit-risk ratio, fondaparinux is approved for the prevention and treatment of venous thromboembolism. Two large trials in about 32000 patients recently evaluated fondaparinux in the treatment of non-ST elevation acute coronary syndromes and ST elevation acute myocardial infarction. Fondaparinux was compared with enoxaparin or usual care, depending on the setting. A single once-daily 2.5 mg subcutaneous dose of fondaparinux was used in both studies. After a brief presentation of the drug, this review presents the results obtained in these trials with fondaparinux and compares them with those obtained with other anticoagulants. Overall, it appears that fondaparinux at the single oncedaily dose of 2.5 mg represents a valuable new alternative for the treatment of patients with acute coronary syndromes. However, fondaparinux cannot be used as stand-alone anticoagulant in the setting of PCI, where an additional of unfractionated heparin is needed to eliminate the risk of catheter thrombus. Full article

► Show Figures

Figure 1

4 pages, 175 KB

Open AccessEditorial

Antithrombin Treatment Strategies for Patients with ST-Elevation Myocardial Infarction

by Nils Kucher, Otto Martin Hess, Christoph Kaiser, Pierre-Frederic Keller, Michael Pieper and Bernhard Meier

Cardiovasc. Med. 2008, 11(9), 274; https://doi.org/10.4414/cvm.2008.01349 - 26 Sep 2008

Viewed by 79

Abstract

Appropriate antithrombotic therapy in patients with ST-elevation myocardial infarction (STEMI) helps reducing major cardiovascular events and bleeding complications. The majority of patients presenting with STEMI in Switzerland are referred for early reperfusion therapy. Primary percutaneous coronary intervention (PCI) has become the preferred reperfusion [...] Read more.

Appropriate antithrombotic therapy in patients with ST-elevation myocardial infarction (STEMI) helps reducing major cardiovascular events and bleeding complications. The majority of patients presenting with STEMI in Switzerland are referred for early reperfusion therapy. Primary percutaneous coronary intervention (PCI) has become the preferred reperfusion strategy and replaced the use of fibrinolysis in many hospitals. Optimal antithrombotic treatment is particularly important during mechanical intervention at the thrombotic coronary occlusion site due to activation of platelets and the clotting cascade. The combination of aspirin, clopidogrel, and glycoprotein IIb/IIIa inhibitors is recommended for STEMI patients undergoing primary PCI. Unfractionated heparin has been used for many years as antithrombin of choice in these patients; it is usually started at the time of presentation and is continued during PCI. The direct thrombin inhibitor bilvalirudin has emerged as promising antithrombotic agent for primary PCI, and a bivalirudin alone strategy without GP IIb/IIIa inhibitor may be especially useful for elderly patients or those with increased risk of bleeding. Antithrombotic treatment regimens for STEMI patients managed conservatively or with fibrinolysis differ from those undergoing primary PCI. Extended-duration therapy with either enoxaparin or fondaparinux for up to 8 days has emerged as antithrombotic regimen of choice for patients not undergoing primary PCI. This article intends to serve as a practical guide to interventional cardiologists and other interested physicians managing patients with STEMI. Current options of anticoagulant drug regimens are summarized from a practical point of view, with special attention to the primary management strategy. Full article

► Show Figures

Figure 1

9 pages, 831 KB

Open AccessEditorial

Mécanismes Physiopathologiques de la Fibrillation Auriculaire

by Amir-Ali Fassa and Dipen C. Shah

Cardiovasc. Med. 2008, 11(9), 265; https://doi.org/10.4414/cvm.2008.01352 - 26 Sep 2008

Viewed by 70

Abstract

The pathophysiology of atrial fibrillation is complex, and appears to result from the interaction between initiating triggers, often in the form of rapidly firing ectopic foci located in the pulmonary veins, and an abnormal atrial tissue substrate capable of maintaining the arrhythmia through [...] Read more.

The pathophysiology of atrial fibrillation is complex, and appears to result from the interaction between initiating triggers, often in the form of rapidly firing ectopic foci located in the pulmonary veins, and an abnormal atrial tissue substrate capable of maintaining the arrhythmia through mechanisms such as multiple wavelet reentry or multiple rotors. Moreover, atrial remodelling, autonomic tone variations and inflammation also may be involved in the genesis and maintenance of atrial fibrillation. Ultimately, the recent understanding of some of these mechanisms has led to new therapeutic strategies, such as radiofrequency catheter and surgical ablation techniques. At the present time, a strategy of radiofrequency catheter ablation tailored to the burden of atrial fibrillation allows efficient management of patients, with a high rate of long-term freedom from recurrence of atrial fibrillation. Full article

► Show Figures

Figure 1

Journal Menu

Journal Browser

Cardiovasc. Med., Volume 11, Issue 9 (09 2008) – 8 articles

Further Information

Guidelines

MDPI Initiatives

Follow MDPI